Keiretsu Forum’s Women of Innovation Award

August 28, 2024 - Keiretsu Forum recognizes Caitlin Cameron, CEO OtoNexus Medical Technologies in a new series, Women of Innovation, to highlight the achievements of female entrepreneurs - See the Full Article Here

OtoNexus Medical Technologies Named Most Valued Company at Keiretsu Forum Investor Capital Expo 2024

OtoNexus Medical Technologies has been recognized as the "Most Valued Company" at the Keiretsu Forum Investor Capital Expo 2024, held on August 15th at the Hyatt Regency Bellevue. The award highlights OtoNexus' innovative contributions to healthcare diagnostics and its potential to reshape the future of children’s healthcare.

The Summer Investor Capital Expo, hosted by Keiretsu Forum, the world's largest angel investor network, brought together over 650 investors, family offices, and industry leaders. The event featured presentations from high-potential startups and emerging companies across various sectors. OtoNexus stood out among the companies for its groundbreaking work in diagnostic technology, drawing significant attention from the Keiretsu investor community.

"We are incredibly honored to receive this recognition,” said Caitlin Cameron, CEO of OtoNexus. "We are excited about our progress and how our technology will transform middle ear infection diagnosis and management, enhancing patient care, reducing unnecessary antibiotic use, and lowering healthcare costs."

The Most Valued Company award reflects the strong interest and confidence that OtoNexus has inspired among the investors. This accolade marks a significant milestone for OtoNexus as it continues to gain traction from investors, partners, and healthcare professionals alike.

OtoNexus Accepted into Prestigious Pediatric Medical Device Accelerator CTIP

SEATTLE, Dec. 12, 2023 /PRNewswire/ -- OtoNexus Medical Technologies Inc., the innovators behind the first ultrasound-based medical device for the instant, accurate assessment of middle ear infections, is proud to announce its recent acceptance into The Consortium for Technology & Innovation in Pediatrics (CTIP). As a leader in pediatric medical device advancement, CTIP is based at two of the nation's foremost children's hospitals, Lurie Children's Hospital and Children's Hospital Los Angeles.

This prestigious affiliation marks a significant milestone for OtoNexus as it joins a robust network of children's hospitals, academic institutions, and industry partners dedicated to improving pediatric healthcare through technological innovation.

"Joining CTIP's accelerator is a testament to the potential of our groundbreaking technology to change the landscape of pediatric care," said Caitlin Cameron, Chair and Chief Executive Officer of OtoNexus Medical Technologies. "We are honored to be a part of this network, working alongside CTIP to guide and support the development of our device, which promises to empower physicians with the right tools to treat middle ear infections with antibiotics judiciously."

The CTIP accelerator, funded by the U.S. Food and Drug Administration Pediatric Device Consortia (PDC) grant program, is designed to promote the development and commercialization of pediatric medical devices. OtoNexus will benefit from direct engagement and access to experts in clinical, engineering, regulatory, hospital administrators, and commercial domains. CTIP's network of children's hospitals, academic institutions, accelerators, and incubators includes 25 organizations across eight states.

OtoNexus's unique technology enables physicians to diagnose middle ear infections swiftly and accurately, thereby facilitating more precise treatments and mitigating the unnecessary use of antibiotics. This aligns with CTIP's mission to address critical gaps in pediatric device innovation.

The acceptance of OtoNexus into CTIP is a promising development for pediatric healthcare providers and the families they serve. The company looks forward to working closely with the CTP network to make a positive impact on the well-being of children across the nation and around the world.

OtoNexus Medical Technologies Selected for Elite FDA STeP Program

SEATTLE, Dec. 6, 2023 /PRNewswire/ -- OtoNexus Medical Technologies, the developer of the Novoscope ultrasound otoscope for immediate and automatic differentiation of bacterial middle ear infections, is excited to announce its recent selection into U. S. Food and Drug Administration Safer Technologies Program (STeP).

STeP is a pioneering initiative introduced by the FDA to identify and expedite the development and review of innovative medical devices that offer a significant advantage over all currently available options, in that devices selected for the program provide radical improvements in patient care and patient safety.  STeP aims to provide patients with more timely access to these medical devices by providing STeP awardees expedited development and review, and interactive and timely communications, including sprint discussions, enhanced regulatory support, real-time feedback and direct advice, and other support.  To qualify, the product must offer a significant advantage over currently available options.

The evaluation process for the program requires comprehensive due diligence by the FDA to ensure the technology meets the strict, extensive criteria. "We are truly honored to be chosen for inclusion in the Safer Technologies Program," stated Caitlin Cameron, Chair and CEO of OtoNexus Medical Technologies. "This program provides a unique opportunity to collaborate closely with the FDA, ensuring that our technology attains the highest levels of safety and efficacy for market clearance with a faster development and review timeline, with a joint goal with the FDA of significantly improving patient safety and patient care."

In 2022, just 14 devices were selected for the elite Safer Technologies Program, an innovative initiative of the Center for Devices and Radiological Health (CDRH) division of the FDA designed to identify and expedite the development of devices expected to significantly improve safety, treatment, and diagnostics.  CDRH oversees 238,000 regulated medical devices and 27,000 device manufacturing firms and received 18,000 total submissions. 

Angel Capital Association Recognizes OtoNexus Medical Technologies as a Winner of Most Investable Company at the 2023 ACA Summit of Angel Investing

SEATTLE, Washington, July 18, 2023 - OtoNexus Medical Technologies Inc. proudly announces its recognition by the Angel Capital Association (ACA) as a winner of the most investable company at this year's highly anticipated ACA Summit, the premier angel investing event of the year.

Sponsored by the prestigious Keiretsu Forum Mid-Atlantic Chapter, OtoNexus Medical Technologies, along with Femly, took center stage at the Innovation Funders Showcase during the ACA Summit. From the impressive lineup of 30 featured companies, attendees overwhelmingly voted OtoNexus and Femly as deserving of a Most Investable Company award.

"The 2023 ACA Summit and Innovation Funders Showcase provided an extraordinary platform for connecting with angel investors and engaging with fellow entrepreneurs," said Caitlin Cameron, CEO of OtoNexus Medical Technologies. "We are truly grateful for this incredible recognition."

OtoNexus Medical Technologies Honored as Top 100 Best Place to Work in Washington State

SEATTLE, June 28, 2023 /PRNewswire/ -- OtoNexus Medical Technologies, a medical device innovator, is celebrating its recognition as one of Washington's 100 Best Workplaces. This award showcases OtoNexus' commitment to fostering an exceptional workplace culture that attracts, retains, and nurtures top talent.

Washington's 100 Best Workplaces program, organized by Puget Sound Business Journal, honors companies prioritizing employee well-being, professional development, work-life balance, and workplace excellence. OtoNexus was one of just 25 Small Businesses selected. OtoNexus ranked #9 in the Small Business Category. The company's inclusion in this prestigious list reflects its continuous efforts to create a collaborative and supportive environment for its employees and its recognition that cohesive, happy teams are high-performing teams who deliver.

"We are honored to be recognized as one of the Top 100 Best Places to Work," said Caitlin Cameron, Chair and CEO at OtoNexus Medical Technologies. "At OtoNexus, we prioritize creating an environment that inspires innovation and encourages collaboration, in which our people can create personal and company success and enjoy their work while they do it. This recognition is a tribute to our incredible team and their unwavering dedication and commitment to positively impacting healthcare."

The distinction of the Top 100 Workplaces is not easily earned. It results from a rigorous evaluation process, including a thorough assessment of employee feedback, workplace policies, and company practices. This recognition is a testament to OtoNexus' commitment to cultivating a positive, inclusive workplace that encourages collaboration, innovation, and growth.

OtoNexus Welcomes Chris Rivera to its Board of Directors

SEATTLE, April 4, 2023 /PRNewswire/ -- OtoNexus Medical Technologies, Inc. is pleased to announce the appointment of Chris Rivera to its Board of Directors.

Mr. Rivera has a demonstrated track record of success in building and exiting life sciences companies throughout his career. He is the Chairman, CEO, and President of EMulate Therapeutics and was the founder and CEO of Hyperion Therapeutics, which Horizon Pharma acquired in 2015. He has held executive leadership roles in many successful companies, including Tercica, Cephalon, Centocor, and Genzyme Therapeutics.

Mr. Rivera has extensive experience in building successful life sciences companies, including leadership, board directorship, business strategy, funding/financing, product launch,

Mr. Rivera also served as President and CEO of Life Science Washington. He helped build the life sciences industry in Washington state and mentored over 400 life science start-up companies. He has also been recognized as a state and national leader through his appointments as co-Chair for the Governor's life science and global health advisory committee, the Governor's Higher Education Task Force, the Washington Global Health Funding Commission, and Chairman of the Board for the National Council of State Bioscience Associations.

Having started his career as an audiologist, Mr. Rivera is particularly interested in OtoNexus' innovative technology and has been an active supporter of the company because of his direct experience in the field. "I am excited to join the OtoNexus Board of Directors and work with the team to advance its innovative technology," said Chris. "I share OtoNexus' philosophy on leadership and building high-performing teams. The company's innovative diagnostic tools and commitment to improving patient outcomes align with my own values and experience. I look forward to working with the team to drive growth and success."

The addition of Chris Rivera to the OtoNexus Board of Directors further strengthens the company's leadership and positions it for success in the life sciences industry.

OtoNexus Medical Technologies Receives Prestigious National Science Foundation Grant

NSF Phase IIB Grant awarded to OtoNexus Medical Technologies for ultrasound platform technology.

SEATTLE, Washington, March 22, 2023 - OtoNexus Medical Technologies is transforming and simplifying how middle ear infections are evaluated with its cutting-edge diagnostic platform.  The company has just announced that it has been awarded a highly prestigious National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase IIB Grant, placing it among an elite group of companies chosen to receive extended funding. The Phase IIB grant is based on the results achieved in Phase I and II and the scientific and technical merit and commercial potential of the OtoNexus technology.

This grant is a significant endorsement of OtoNexus' technology, which uses novel ultrasound technology to diagnose middle ear infections in just seconds. Current diagnostic methods can be unreliable and often lead to unnecessary antibiotics, but the OtoNexus platform provides a non-invasive, rapid, and accurate alternative.

Caitlin Cameron, CEO of OtoNexus, expressed her pride in the company's achievement, stating, "It is a tremendous honor to receive this grant from the NSF. We are thrilled to have our groundbreaking technology recognized and supported in this way."

Middle ear infections, or otitis media, are a common childhood illness. The OtoNexus platform provides a game-changing solution to diagnosing and managing these infections, helping healthcare providers deliver better patient outcomes.

Caitlin Cameron, Panelist at Prestigious Rainier Club Medical Innovation Event, Seattle, WA

February 7, 2023

Caitlin Cameron, Chair and CEO, was recently featured as a guest panelist at the prestigious Rainier Club in Seattle, Washington. The topic of the event was medical innovation, and Caitlin’s expertise and experience in the field made her a perfect fit for the panel.

As the leader of OtoNexus, an innovative medical device company, Caitlin has a wealth of knowledge and insights on the latest advancement in the industry. Attendees of the event had to the opportunity to hear Caitlin share her thoughts on the future of medical innovation and how it will impact the healthcare industry. Her passion for her work and commitment to improving patient care was evident throughout the discussion, and she received high praise from the attendees.

Caitlin’s appearance at the Rainier Club was a testament to her status as a thought leader in the field of medical innovation.

JoAnn Corkran, Co-CEO and Managing Partner of Golden Seeds, LLC Highlights OtoNexus Medical Technologies on NASDAQ TRADETALKS  

Golden Seeds invests in early-stage women-led companies.  Since 2005 Golden Seeds has invested 175 million nationwide in women-led companies that went on to raise over 2 billion dollars.  Golden Seeds LLC is one of the largest and most active groups.  They have 350 investors that invest in 30 companies annually.

Recently, JoAnn joined Jill Malandrino on NASDAQ TRADETALKS to discuss the outlook for 2023 in early-stage investing.  Golden Seeds LLC invests in three sectors that are B2B women-led companies that focus on Software, Healthcare, and Consumer Goods.

JoAnn emphasizes that “Women dominate innovation in healthcare. An example is a company they invested in, which is developing an otoscope that uses ultrasound to detect if you have a bacterial infection to drive down the use of antibiotics”.

OtoNexus is delighted to receive such prestigious recognition from this well-established investment group on an influential broadcast such as NASDAQ TRADETALKS. 

To hear JoAnn Corkran’s full interview, click here:

OtoNexus Medical Technologies Awarded Top 10 Infection Control Solution Providers 2022 by MedTech Outlook

July 7, 2022

We are excited to share the news!  OtoNexus was honored as a Top Infection Control Solution Provider by MedTech Outlook.  OtoNexus was one of 10 companies selected nationwide as “companies that are at the forefront of providing infection control solutions and impacting the industry.”  By providing the data that physicians need to practice responsible antimicrobial stewardship, OtoNexus enables physicians to prescribe antibiotics judiciously. The OtoNexus device provides a quantitative score to identify fluid presence and type of infection. This data provides a clear picture of the middle ear infection, resulting in faster treatment decisions. To read the full article, visit MedTech Outlook.

Puget Sound Business Journal Straight Talk Series Innovations in Health Care

October 19, 2021

Caitlin Cameron, CEO, OtoNexus Technologies participated in the Puget Sound Business Journal Straight Talk: Innovations in Healthcare. The series brings together experts from the Puget Sound area to discuss trends in the healthcare innovation industry.

Caitlin noted improvement in care can be achieved with more focus on healthcare innovation on tools for primary care physicians. This would provide the tools they need to effectively screen for disease and manage care early in the patient care pathway.

Listen to the full event here.

Insights Success lists OtoNexus as one of the 10 most Innovative Infection Prevention Solution Providers in 2021

September 21, 2021

Insights Success selected OtoNexus as one of 10 most innovative infection prevention solution companies that are at the forefront of providing infection control solutions and having an impact on the industry.

To see the full story visit Insights Success OtoNexus Medical Technologies: Bringing a Novel Approach in Assessing Middle Ear Infections.

OtoNexus Selected for MedTech Innovator Accelerator and Showcase Program

June 15, 2021

MedTech Innovator, the largest accelerator of medical device companies in the world has selected OtoNexus Medical Technologies to participate in the organization’s flagship four-month Showcase and Accelerator program. OtoNexus was selected from over 1,100 applications to participate. The program culminates at the MedTech Conference, powered by AdvaMed, on September 27-29, where OtoNexus will present in the Showcase panel. More information on the program is available at MedTech Innovator.

OtoNexus Awarded Southwest Pediatric Device Consortium Grant

June 5, 2021

OtoNexus Medical Technologies was selected by the Southwest Pediatric Device Consortium, Baylor College of Medicine, Texas Children’s Hospital for the Faculty Seed Grant for the 2021-2022 program. The grant is sponsored by the Baylor College of Medicine Office of Research to support Baylor College of Medicine faculty members to pilot clinical studies with novel pediatric medical devices. OtoNexus is delighted to work with this prestigious institution and faculty. More information is available at SWPDC

OtoNexus Medical Technologies Wins 2020 Red Herring Top 100 North America Award

SEATTLE, November 20, 2020/PRNewswire/ - Red Herring announced the winners of its Top 100 North America event, recognizing the continent's most exciting and innovative private technology companies.

The winners were chosen from thousands of entrants, whittled down to hundreds presenting their companies at the virtual conference on November 17th and 18th. 2020's crop of Top 100 winners has been among our most intriguing yet," said Vieux. "North America has led the way in tech for so many years, and to see such unique, pioneering entrepreneurs and companies here, which is in many ways the heartland of the industry, has been a thrilling experience.

For more information, view the full press release.

OtoNexus Medical Technologies Wins Prestigious Most Valued Company Award at Keiretsu Forum Investor Capital Expo

SEATTLE, November 10, 2020 /PRNewswire/ - Keiretsu Forum announced that OtoNexus Medical Technologies was named ‘Most Valued Company’ at the Keiretsu Forum Investor Capital Expo. Investors selected OtoNexus from a highly competitive company showcase featuring 36 growth stage companies. Nearly 50 angel groups, investors from 100+ Family Offices, corporate partners, and hundreds of accredited investors attended the event. "Now winning the Most Valued Company award for the third time, our investors have consistently voted OtoNexus a tremendous growth-stage opportunity, and as an example of the high-quality deal-flow, we have seen throughout 2020, particularly in life sciences and technology. OtoNexus is also a showcase for how angel funding can be leveraged from seed to syndication of growth-stage deals, and a strategic catalyst to finalize product development and testing for market introduction," said Nathan McDonald, Chairman, Keiretsu Forum Northwest & Rockies Region.

For more information view the full press release.

OtoNexus Medical Technologies Selected by The Silicon Review as one of 50 Innovative Companies to Watch 2020

October 22, 2020

We are honored to receive this prestigious recognition by The Silicon Review. OtoNexus was included with a diverse range of companies - pharma, AI Deep Learning, cloud-based business, retail management software and security services to name a few.

OtoNexus has produced the first advanced ultrasound otoscope that evaluates a middle ear infection and determines the type of fluid present. The device is designed for primary care providers and has the familiar look and feel of the otoscope they use everyday. The only difference is now they push a button to measure and in less than 2 seconds they can determine when antibacterial therapy is appropriate. To see the full story visit The Silicon Review.

OtoNexus Medical Technologies Selected as Top Infection Control Solution Provider by MedTech Outlook

August 20, 2020

We are excited to share the news!  On August 20, 2020, OtoNexus was honored as a Top Infection Control Solution Provider by MedTech Outlook.  OtoNexus was one of 10 companies selected nationwide as “companies that are at the forefront of providing infection control solutions and impacting the industry.”  By providing the data that physicians need to practice responsible antimicrobial stewardship, OtoNexus enables physicians to reduce antibiotic prescriptions to only when necessary. This is important for two reasons. First, if antibiotics are taken when they are not needed, they can place the child at a higher health risk.  Second, the development of resistant organisms (super-bugs) is a global healthcare challenge. To read the full article visit MedTech Outlook.

OtoNexus Medical Technologies Receives 4th Consecutive Funding Round from Keiretsu Capital

SEATTLE, July 9, 2020 /PRNewsCentre/ — OtoNexus Medical Technologies Inc., announced today that Keiretsu Capital has invested in OtoNexus for the fourth time. Keiretsu Capital and Keiretsu Forum members are leading investors in OtoNexus with a total of $13 million in funding since the company’s inception. The new investment round enables OtoNexus to finalize product development and testing for market introduction. 

OtoNexus has developed the world’s first ultrasound hand-held device to evaluate the four disease states of middle ear infection. With the tools available today, detection accuracy is approximately 50%, in the key differentiation of viral versus bacterial infections. As a result, middle ear infections are the #1 reason for antibiotic prescriptions and #1 reason for surgery in children.  

For more information view full press release

Caitlin Cameron Recognized as Life Sciences Executive of the Year by Puget Sound Business Journal

December 6, 2019

The Puget Sound Business Journal announced it’s Health Care Leadership Awards, a celebration of the outstanding leaders in health care around the greater Puget Sound area.  The awards recognize people on the front lines of the health care industry who are innovative and influential thinkers whose leadership has had a lasting impact on the region. 

We are honored that Caitlin Cameron was recognized as Life Sciences Executive of the Year.  In honor of the leadership awards event, Puget Sound Business Journal created a special edition published for the honorees.  Caitlin was prominently featured with a full two-page interview called She hopes to reduce the need for antibiotics in children.  It is no surprise to learn that Caitlin started her first business with her brother at a very early age and was running a 13-store retail operation at 18.  It is very clear that she was a CEO in training from the beginning!  

Caitlin is a huge advocate for the Life Science community in the Puget Sound area and works with numerous programs and associations to support entrepreneurs and business leaders.  

Click the article title to view the Puget Sound Business Journal Article - She hopes to reduce the need for antibiotics in children.

OtoNexus Awarded Washington State Scholarship

November 18, 2019

We have just completed an exhibition at MEDICA, the world’s largest healthcare trade show. We were selected by the Washington State Department of Commerce for a scholarship to join the state delegation to be a part of the Washington State Pavilion. Our theme for the event was Responsible Antimicrobial Stewardship. Presentations described the negative impact that the inadequate treatment of otitis media has on both patient care and healthcare costs. OtoNexus was also prominently featured in an article in the European Hospital Magazine’s special MEDICA publication on the first day of the event.

Keiretsu Forum Mid-Atlantic Investor Capital Expo

October 16, 2019

Every year Keiretsu Forum Mid-Atlantic's Investor Capital Expo hosts an event to showcase new businesses and innovation to their investors.  This year the event was hosted in Philadelphia on October 15-17th.  In 2018 the Keiretsu Forum Mid-Atlantic Region received more than 315 applications, screened 130, and invited 40 to present at the monthly Forum meetings.

Over 200 investors participated in the event, and 11 early-stage entrepreneurs were selected. OtoNexus rose above all the other contenders to win the Stephen M. Goodman Most Valued Company Award for 2019.

Future in Review 2019

October 6, 2019

Future in Review (FiRe) previously selected OtoNexus as a FiReStarter Company.  OtoNexus was honored this year with an invitation to the conference and participate in the panel discussions.  Caitlin Cameron and Charlie Corredor both participated in the panel discussions. 

Now in its 13th year, the FiReStarter Program annually showcases up to 12 businesses to participate in the event.  FiReStarter partners with the Strategic News Service to choose the participants.  The companies selected demonstrate the potential to improve our world.  We were overjoyed that FiRe 2019 chose OtoNexus as the Company of the Year.

Keiretsu Northwest Angel Capital Expo

October 9, 2019

Based in Seattle, Washington, the Keiretsu Forum Northwest Region is part of the broader Keiretsu Forum, the world’s largest and most active angel investor network. OtoNexus was chosen as an investment for Kerietsu’s angel members as well as the Keiretsu Capital Funds, which co-invests in promising companies. OtoNexus was voted the Most Valued Company by hundreds of investors attending the Keiretsu Angel Capital Expo. OtoNexus was selected from 20 companies that presented and exhibited at the Expo.

Caitlin is seen here with this beautiful award presented by Brianna McDonald, President, and Nathan McDonald, Chairman Keiretsu Forum Northwest Region.

Life Science Washington

October 2, 2019

The Seattle area is well known as the City of Ultrasound Technologies. There is a very strong medical device community with several professional groups for industry members to meet and share ideas about innovation in this field.  Life Science Washington is a prominent organization in the area that regularly hosts events for the community.  Recently Life Science Washington Product Creation Studio and FUJIFILM SonoSite Inc sponsored an event in Bothell, WA.  This event was the 4th series this year focused on medical device innovation and ultrasound of the future. 

OtoNexus Wins WomenCorporateDirectors Launch Zone Competition

June 19th, 2019

We are delighted to announce being voted winner of the WomenCorporateDirectors Foundation (WCD) “Launch Zone” competition for women-led companies, held in Santa Clara, CA. OtoNexus presented before a panel of judges representing angel investors, private equity, and investment banking. The audience comprised more than 200 women corporate board members from 23 countries–attendees of the 2019 WCD Global Institute, WCD’s largest membership gathering of the year. Both attendees and judges voted, with OtoNexus winning both the audience and the judges’ votes. The WCD is a prestigious organization that focuses on supporting female entrepreneurs.

OtoNexus Awarded Another Federal Grant - National Science Foundation (NSF) Phase II SBIR Grant

March 19th, 2019

OtoNexus was honored to be awarded a National Science Foundation (NSF) SBIR Phase II Grant, covering key elements of our product development. This grant was a follow-on grant to our successful NSF Phase I grant. Companies funded by NSF SBIR Phase II grants have demonstrated transformational technology with enormous potential societal and market impact, presenting a unique and significant opportunity to change the status quo.

OtoNexus Medical Technologies and Fraunhofer IPMS Partnership

November 12th, 2018

OtoNexus is pleased to announce our partnership with Fraunhofer IPMS (Dresden, Germany) to continue the development of our ultrasound transducers.

OtoNexus Debuts at MEDICA

November 11th, 2018

OtoNexus exhibited at MEDICA, the largest medical industry trade show in the world, and the premier place for companies like ours to introduce innovative technologies to the medical world. MEDICA is held each year in Düsseldorf, Germany and is attended by 150,000+ attendees from around the world, not counting exhibitors. This was an important opportunity to present our disruptive technology to the medical world and allowed OtoNexus to establish new relationships for local and international partnerships.

MedTech Strategist Features OtoNexus in Startups to Watch

October 31st, 2018

MedTech Strategist, an important industry publication in the medical device field, publishes its Startups to Watch series to spotlight up-and-comers in the medical device industry. Following a lengthy interview, the MedTech Strategist described our vision on diagnosis for otitis media and the current market need for our device. OtoNexus is described as an easy-to- use handheld device that can identify the presence and type of infection in the middle ear in seconds, matching clinician’s current steps, workflow, and standard of care (MedTech Link).

CEO Cameron presents at the Angel Investing in Women-Led Companies event hosted by Golden Seeds and the Anita Borg Institute

October 30th, 2018

Caitlin Cameron, Chair and CEO, was delighted to be a panelist at the Angel Investing in Women-Led Companies event hosted by Golden Seeds and the Anita Borg Institute in Palo Alto, CA. This event was a great opportunity for Caitlin to share her vision and experience with entrepreneurs and the investors community and talk about how to build successful companies.

Caitlin Cameron chosen as a finalist for 2018 EY’s Pacific Northwest Entrepreneur of the Year

May 8th, 2018

EY’s annual Entrepreneur of the Year program recognizes the endeavors of top entrepreneur leaders who create products or services that keep our worldwide economy moving forward. Since its inception, Entrepreneur of The Year has grown dramatically and now includes programs in more than 60 countries and 145 cities worldwide. Caitlin was a finalist for this prestigious award, recognizing her leadership and success leading OtoNexus Medical Technologies. (GeekWire Link)

Life Science Washington (LSW) Spotlight: A conversation with LSW’s new Board Chair, Caitlin Cameron

April 12th, 2018

Life Science Washington recently sat down with our CEO, Caitlin Cameron, to get her perspective on Washington’s life science ecosystem, LSW’s role in it, and her vision for the industry’s future. (LSW Link)

Caitlin Cameron Selected as Board Chair of Life Science Washington (LSW)

December 27th, 2017

Life Science Washington, the trade association for Washington state’s life sciences and biotechnology industries and one of the largest Life Science trade associations in the US, appointed OtoNexus Medical Technologies Chair & CEO Caitlin Cameron as the Chair of its Board of Directors for 2018 and 2019.  It is an honor to have our CEO chosen to lead and represent the life science community in Washington (GeekWire Link).

Mayo Clinic Pediatric Days

October 17th, 2017

OtoNexus is honored to have been invited by Mayo Clinic to participate in The Mayo Clinic Pediatric Days. This prestigious event was attended by pediatricians and pediatric nurse practitioners. It was an opportunity to introduce our clinical solution to attendees and get invaluable pre-launch feedback. Mayo Clinic has a very strong focus on antimicrobial stewardship and provided courses on helping clinicians manage parental pressure to prescribe antibiotics. The response to our technology was tremendous and strongly reinforced the need for our simple and elegant diagnostic tool.

Entrepreneur Boot Camp

November 5th, 2017

Our CEO, Caitlin Cameron, was a key speaker at the Entrepreneur Boot Camp hosted by Keiretsu Forum and Microsoft. Caitlin provided training for entrepreneurs and investors on “Building to Exit”.  The training focused on how to build a company for a successful exit and highlighted the need to build the exit plan into the company plan and actions from “Day One”. This training has since been requested and repeated many times.

National Science Foundation (NSF) Phase I SBIR Grant

July 17th, 2017

OtoNexus was also awarded a National Science Foundation (NSF) SBIR Phase I Grant for $225,000. NSF is known to place greater emphasize on technology innovation and the commercial potential of the company.

National Institute of Health (NIH) Fast-Track SBIR Grant

June 10th, 2017

OtoNexus was honored to have been awarded a Fast-Track SBIR Grant from the National Institutes of Health (NIH) for $1.15 Million. Fast-Track grants combine Phase I and Phase II, and are much more competitive than standard grants. This is a wonderful endorsement of our technology by NIH.

OtoNexus awarded AdvaMed Scholarship

October 21st, 2016

AdvaMed, the MedTech Conference, the leading event for medical technology professionals in North America, announced today that 48 early-stage companies have been selected to participate in the Innovation Showcase, an exhibition presenting the latest medtech innovations, offered under scholarships provided by sponsor organizations. OtoNexus was delighted to been selected for this award.

OtoNexus Selected by Future in Review (FiRe) as a FiReStarter Company

July 9th, 2016

OtoNexus is honored to have been selected by Future in Review (FiRe) as a FiReStarter Company!  As a result, the company will be featured at the 14th Annual Future in Review Conference in Park City, Utah, September 27-30.  This conference is described by The Economist magazine as “The best technology conference in the world.”

Future in Review (FiRe) is focused on predicting the future, identifying likely outcomes and what technology will have the greatest impact in determining what lies ahead - and they have been amazingly accurate in their predictions.    Their focus related to young companies like ours is to identify the few that they believe have the greatest potential for bringing about transformative change.  They select only twelve companies each year, from nominations from across the globe.

Being designated as a FiReStarter Company is a rare and highly coveted honor that puts OtoNexus in an elite class – Tesla was an early FiRe honoree.

Joining us for this event will be the top leaders of technology, finance and telecommunications, in addition to top levels of global press. Click here for more information about the conference: www.futureinreview.com. Click here for the press release.

OtoNexus Wins Angel Capital Association Innovation Showcase

May 18th, 2016

OtoNexus was nominated for and subsequently honored with being selected to be a part of the Angel Capital Association’s Innovation Showcase, at this year’s ACA Annual Summit in Philadelphia.  Fifty companies were selected to be a part of the Showcase from nominations from around the country.  This was a juried event; just being selected to be in the Showcase was a big win.  

At the event, all Angels voted for the Innovation Showcase companies they felt were the best. At the final Keynote, the winners were announced.  OtoNexus was selected as the National Winner of the Innovation Showcase!

Winner of Seattle's InnovateHER Competition

April 5th, 2016

OtoNexus Medical Technologies is delighted to have been selected as the winner of Seattle’s InnovateHER Showcase.  InnovateHER: Innovating for Women Business Showcase is a Small Business Association (SBA) initiative in support of women-owned and women-led businesses.  InnovateHER in Seattle was sponsored by Microsoft Ventures.  More than 30 companies participated; eight made it to the final round, and OtoNexus was selected as the winner out of a terrific field of women-owned and women-led businesses.